Segment Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Revenue, Major Customer [Line Items]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The Company’s CODM, its Chief Executive Officer, views the Company’s operations and manages the business as one operating segment focused on the development and commercialization of gene therapies to treat an array of diseases.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Cash, Cash Equivalents, and Short-Term Investments, Total	$ 272.7		$ 244.9
Interest income from investments	$ 2.5	$ 2.5